Slide background
Slide background

Rapporto ECHA: Impatti socioeconomici delle autorizzazioni REACH

ID 4634 | | Visite: 1567 | Documenti Chemicals ECHAPermalink: https://www.certifico.com/id/4634

Report: ECHA’s scrutiny has a profound impact on authorisation decisions

Helsinki, 18 September 2017

According to ECHA’s report the requirements for authorisation have introduced stricter controls of use and have therefore reduced risks from harmful chemicals to workers and the population at large. They have often led to early substitution to safer alternatives. Where applicants made a convincing case that substitution was not possible the recommended authorisations permit them to continue using substances of very high concern and to avoid substantial costs to society.

The authorisation system has entailed costs to applicants and regulatory authorities, but the benefits outweigh the remaining risks, based on ECHA’s analysis of the first 100 applications for authorisation submitted and evaluated by the end of 2016.

The authorisation requirements as well as the reputational issues of continued use of substances of very high concern (SVHCs) have driven companies to substitute hazardous substances with safer alternatives as witnessed by the non-receipt of applications for seven substances on the Authorisation list.

Substitution of substances on the REACH Authorisation List is taking place. No applications were received for seven substances and several applications contained planned substitution activities.   

Three findings stand out:

- Whilst the remaining risks associated with the continued use of SVHCs are important, the risk reductions brought about by the authorisation system have reduced the exposure to harmful chemicals of workers and the population at large. Thereby, the authorisation system has helped to lower the burden of occupational and other diseases in the EU.

- The aggregate benefit of authorisations (i.e. the costs that applicants, their clients and society as a whole would have to bear if the authorisations had not been granted) were estimated to outweigh the remaining monetised risks to human health and the environment by on average a factor of 15 to 1. This ratio varied a lot from one application to another.

- While ECHA’s scientific committees recommended to the European Commission that all the authorisations be granted, they suggested additional conditions and/or monitoring requirements in two-thirds of the uses. Furthermore, they recommended that the review periods be – on average – 2.5 years shorter than proposed by the applicants. Thus, the scientific scrutiny of the applications manifests itself in the opinion-making process.

The authorisation title of the REACH Regulation is a new way of approaching the management of hazardous chemicals, which incentivises firms in the European Union (EU) to substitute away from SVHCs where this is feasible.

In particular, SVHCs listed under Annex XIV to REACH must not be used after a specified sunset date unless a user or their supplier (e.g. the manufacturer or importer of the substance) hold an authorisation.

For substances for which a threshold in accordance with Annex I to REACH was established authorisations must be granted if the risk to human health or the environment from the use applied for is adequately controlled. Authorisations for substances for which it is not possible to determine a threshold may be granted if suitable alternatives to the specific use of the substance are not available and the applicant can credibly show that the socio-economic benefits of continuing its SVHC use beyond the sunset date outweigh the associated risk to human health and the environment.

The REACH authorisation title provides a flexible policy tool to manage the risks associated with the use of SVHCs. Together with EU Member States, the European Commission adds substances to Annex XIV to REACH. This ‘authorisation list’ includes substances which:

(i) are carcinogenic, mutagenic or toxic to reproduction (CMR);
(ii) are persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB); or
(iii) give rise to an equivalent level of concern (e.g. endocrine disrupters).

Firms, in turn, decide whether they wish to use a specific substance after the sunset date — and thus apply for authorisation on their own or under the umbrella of an upstream application — or discontinue the use of the substance.

ECHA and its scientific committees then examine the claims made by the applicants in their applications and forward an opinion on each application to the European Commission, which then decides together with the Member States whether and for how long an authorisation will be granted.

As of May 2017, ECHA had received 115 applications for authorisation for 199 of some 20 different SVHCs. Each of these applications includes a specification of the substance and the use for which authorisation was applied for, supported by a chemical safety report (CSR), an analysis of alternatives (AoA) and a socio-economic analysis (SEA).

ECHA’s Committee for Risk Assessment (RAC) assesses the risks to human health and the environment arising from the specific use of the substance as well as the appropriateness and effectiveness of the risk management measures as described in the CSR. ECHA’s Committee for Socio-economic Analysis (SEAC) examines the applicant’s report on the availability and suitability of alternatives for the use applied for and assesses the socio-economic consequences of the authorisation decision. RAC and SEAC then provide a joint opinion to the European Commission for supporting regulatory decisions.

Fonte: ECHA

Correlati:

Candidate list ECHA: Sostanze estremamente preoccupanti SVHC

ebook Regolamento REACH

Scarica questo file (Socio-economic impacts of REACH authorisation.pdf)Socio-economic impacts of REACH authorisation.pdfECHA Settembre 2017EN1043 kB(203 Downloads)

Tags: Chemicals Candidate list Guida ECHA

Articoli correlati

Ultimi archiviati Chemicals

EIGA 219 2019
Mag 11, 2019 57

Guideline for Validation of ASU and Cargo Transport Unit

Guideline for Validation of Air Separation Unit and Cargo Transport Unit Filling for Medical Oxygen and Medical Nitrogen EIGA Doc. 219/19 This publication provides the EIGA position and guidance on the manufacturing, bulk product storage, and cargo transport unit (cryogenic tankers and containers)… Leggi tutto
218 19
Mag 09, 2019 63

Medicinal VIPR Package

Medicinal VIPR Package - Lifetime Performance of Drug Delivery Device EIGA Doc. 218/19 One of the major developments on how medicinal gases are delivered to patients has been the introduction of cylinders fitted with valves that have an integrated pressure regulator. These medical gas cylinder… Leggi tutto
Decisione 2019 701
Mag 08, 2019 130

Decisione (UE) 2019/701

Decisione (UE) 2019/701 della Commissione del 5 aprile 2019 che stabilisce un glossario delle denominazioni comuni degli ingredienti da utilizzare nell’etichettatura dei prodotti cosmetici GU L 121/1 dell'08.05.2019 Entrata in vigore: 28.05.2019 Articolo 1 Il glossario delle denominazioni comuni… Leggi tutto
Prassi di riferimento 57 2019
Mag 07, 2019 80

UNI/PdR 57:2019 prodotti alimentari e bevande senza additivi

Prassi di riferimento UNI/PdR 57:2019 in materia di prodotti alimentari e bevande senza additivi L’obiettivo della prassi di riferimento è quello di definire le linee guida per prodotti alimentari e bevande e, in particolare: [alert]- fissare quali siano i requisiti ai quali gli alimenti e le… Leggi tutto
Mag 07, 2019 101

Regolamento (UE) 2019/698

Regolamento (UE) 2019/698 Regolamento (UE) 2019/698 della Commissione del 30 aprile 2019 che modifica gli allegati III e V del regolamento (CE) n. 1223/2009 del Parlamento europeo e del Consiglio sui prodotti cosmetici GU L del 07.05.2019 Entrata in vigore: 27.05.2019 ________ Articolo 1L'allegato… Leggi tutto
Mag 03, 2019 98

Rettifica del regolamento (CE) n. 1272/2008 | 03.05.2019

Rettifica del regolamento (CE) n. 1272/2008 | 03.05.2019 Rettifica del regolamento (CE) n. 1272/2008 del Parlamento europeo e del Consiglio, del 16 dicembre 2008, relativo alla classificazione, all'etichettatura e all'imballaggio delle sostanze e delle miscele che modifica e abroga le direttive… Leggi tutto
Mag 02, 2019 94

Regolamento (UE) 2019/681

Regolamento (UE) 2019/681 della Commissione del 30 aprile 2019 che modifica l'allegato II del regolamento (CE) n. 1223/2009 del Parlamento europeo e del Consiglio sui prodotti cosmetici GU L 115/5 del 02.05.2019 Entrata in vigore: 22.05.2019 Articolo 1 L'allegato II del regolamento (CE) n.… Leggi tutto
Mag 02, 2019 105

Regolamento (UE) 2019/680

Regolamento (UE) 2019/680 della Commissione del 30 aprile 2019 che modifica l'allegato VI del regolamento (CE) n. 1223/2009 del Parlamento europeo e del Consiglio sui prodotti cosmetici GU L 115/3 del 02.05.2019 Entrata in vigore: 22.05.2019 Articolo 1 L'allegato VI del regolamento (CE) n.… Leggi tutto
Linee guida OCSE e UE ai test
Mag 01, 2019 98

Linee guida OCSE e UE ai test

Linee guida OCSE e UE ai test Gli studi ai sensi delle prescrizioni in materia di informazioni sull'ecotossicità, la tossicità e le proprietà fisico-chimiche sono solitamente condotti sulla base di linee guida per le sperimentazioni, che sono state approvate dall'OCSE e dall'UE. In seguito agli… Leggi tutto

Più letti Chemicals

Mar 02, 2019 17265

Regolamento (CE) n. 2023/2006 (Regolamento GMP)

Regolamento (CE) n. 2023/2006 Regolamento (CE) N. 2023/2006 della Commissione del 22 dicembre 2006 sulle buone pratiche di fabbricazione dei materiali e degli oggetti destinati a venire a contatto con prodotti alimentari (Regolamento GMP - Good Manufacturing Practices) ... Il presente regolamento… Leggi tutto